Deals: Page 78
-
Why CNS drug maker Acadia's shares soared on Tuesday
Rumors of a buy-out have been propelled by Acadia canceling two investor's conferences in a row, sending its stock soaring.
By Nicole Gray • March 11, 2015 -
Ackman becomes Valeant's 5th largest shareholder with $3.3B gamble
With Ackman's latest investment, Pershing Square now owns 4.9% of Valeant.
By Nicole Gray • March 9, 2015 -
AbbVie beats out J&J, will buy Pharmacyclics for $21B to boost cancer pipeline
With lower Humira sales on the horizon, AbbVie will get a big boost from Pharmacyclics' expected cancer blockbuster Imbruvica.
By Sy Mukherjee • March 5, 2015 -
The post-acquisition cuts begin: Valeant lays off 77 Dendreon employees
As of February 23, Valeant started laying off the 77 Dendreon employees slated for termination after the now-defunct company's $495 million acquisition by Valeant.
By Nicole Gray • March 4, 2015 -
AZ board to CEO Soriot: Want that big bonus? Show us the money
After successfully staving off a Pfizer takeover last year, the AZ CEO promised revenues of $45 billion by 2023. But sales are down, and now Soriot's bonus is at stake.
By Nicole Gray • March 3, 2015 -
Gilead seals generic Sovaldi deal with Natco, NICE rec for Harvoni in UK
India-based Natco Pharma will sell generic Sovaldi (sofosbuvir) and other hep C drugs in 91 countries. And Harvoni will come at a steep discount compared to the U.S. in the UK.
By Nicole Gray • March 3, 2015 -
Ousted Sanofi chief Chris Viebacher lands at PureTech
Viehbacher is joining the company, a Boston-based healthcare R&D firm, as a member of its Board of Directors.
By Nicole Gray • March 2, 2015 -
Pharmacyclics surges on news of potential sale to J&J, Novartis
It could become the biggest biotech deal since Sanofi/Genzyme.
By Nicole Gray • Feb. 26, 2015 -
Merck, MPP team up to provide low-cost HIV pediatric meds in poor countries
Merck's Isentress (raltegravir) is the only integrase inhibitor approved for pediatric treatment.
By Nicole Gray • Feb. 25, 2015 -
French government slams Sanofi over new CEO's pay
One government spokesperson called Olivier Brandicourt's pay package, which includes a $4.5 million entry bonus, "incomprehensible."
By Nicole Gray • Feb. 25, 2015 -
Shire keeps acquisition train rolling with $70M Meritage Pharma deal
Through the Meritage acquisition, Shire is gaining a phase 3 treatment for a rare GI disorder.
By Nicole Gray • Feb. 25, 2015 -
Platinum parachute? Allergan CEO Pyott could get $100M exit fee
Actavis has said that it will replace most of Allergan's executives with its own post-merger.
By Nicole Gray • Feb. 25, 2015 -
Pfizer planning more layoffs in R&D
The company also says it will be adding positions in immuno-oncology and gene therapy as part of a new round of restructuring.
By Sy Mukherjee • Feb. 24, 2015 -
Duchenne, orphan drug maker PTC Therapeutics fielding takeover bids
According to an exclusive report from Reuters.
By Nicole Gray • Feb. 24, 2015 -
Cellectis files $115M IPO to fund unique CAR-T program
The CAR-T competition is heating up as Cellectis, based in Paris, brings a new approach to cancer immunotherapy using allogeneic treatments.
By Nicole Gray • Feb. 22, 2015 -
UPDATE: Valeant to buy Salix for $10.1B, cleared for $495M Dendreon buyout
And company CEO Michael Pearson said on Monday that smaller deals are still on the horizon.
By Sy Mukherjee • Feb. 20, 2015 -
UPDATE: Bayer HealthCare chief Brandicourt named Sanofi's next CEO
Four months after the ouster of former Sanofi CEO Chris Viehbacher, the company has decided to hire a pharma veteran. But just how much power will Brandicourt have?
By Nicole Gray , Sy Mukherjee • Feb. 19, 2015 -
The more, the merrier? Endo also pursuing Salix Pharma bid
On top of Valeant and Shire.
By Nicole Gray • Feb. 18, 2015 -
Can AZ finally solidify a deal for its anti-infectives unit?
For more than a year, AstraZeneca has been shopping a partnership deal for its anti-infectives unit. But there don't seem to be any takers—and the clock is ticking.
By Nicole Gray • Feb. 17, 2015 -
Valeant arranges financing for potential Salix Pharma bid
Now that Valeant has secured sufficient funding, it is better positioned to make a bid for gastroenterology-focused Salix Pharmaceuticals.
By Nicole Gray • Feb. 13, 2015 -
Indian pharma giants scuffle to snap up injectables maker Claris
Claris Lifesciences, based in Ahmedabad, focuses on generic sterile injectables—an area where demand currently outweighs supply.
By Nicole Gray • Feb. 13, 2015 -
Shire raises 2015 forecast on NPS acquisition
After striking a $5.2 billion deal for NJ-based NPS Pharma last month, Shire, which is based in Ireland, is forecasting growth in the 5% to 9% range.
By Nicole Gray • Feb. 12, 2015 -
Hospira CEO's golden parachute for Pfizer deal: $80 million
That includes stock options and tax payments.
By Sy Mukherjee • Feb. 12, 2015 -
GSK broadens vax portfolio with $190M GlycoVaxyn deal
This is on top of a $5.25 billion vaccine deal with Novartis.
By Nicole Gray • Feb. 12, 2015 -
Gilead to open London HQ, double UK workforce
The new HQ will cost $19.6 million.
By Sy Mukherjee • Feb. 10, 2015